J.P. Morgan Says Acorda Troubling Parkinson’s Trial Lessens Upside Potential

Acorda Therapeutics Inc (NASDAQ:ACOR) shareholders are spooked right now after the drug maker confirmed yesterday that enrollment in two long-term safety trials for Parkinson’s asset tozadenant is paused on the heels of 5 deaths from sepsis. In the aftermath, J.P. Morgan analyst Cory Kasimov points to rising pipeline skepticism, cutting his price target.

Story Continues

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts